Peptech to advance anti-TNF drug after preclinical study
Wednesday, 08 June, 2005
Peptech (ASX:PTD) has claimed "significant" results in a preclinical study of its human domain antibody (dAb) therapeutic -- potency levels three times higher than the current market-leading anti-TNF drug against rheumatoid arthritis.
Peptech's domain antibody against tumour necrosis factor alpha (TNF) -- used for the treatment of multiple inflammatory diseases such as rheumatoid arthritis and Crohn's disease -- successfully suppressed disease development, the company said.
R&D director Dr Phil Jennings said the study gave Peptech confidence that the drug could be commercialised, and had potential to become one of the next generation in anti-inflammatory treatments.
"Our focus is on continuing to advance the preclinical development of the anti-TNF dAb, with an expectation of reaching the clinic in 2007," he said in a statement.
The study was completed under a research agreement between Peptech and UK company Domantis, in which Peptech has a 36.1 per cent stake. Peptech said it had since further engineered the dAb based protein to enhance its characteristics as a human therapeutic.
Peptech's executive chairman, Mel Bridges, said therapeutic biologicals represented a major commercial opportunity, with the company's anti-TNF dAb targeted at a market with 2004 product sales of more than $US6 billion.
"We hold a very strong intellectual property position in anti-TNFs, and are in the enviable position of receiving ongoing strong revenue streams from our existing TNF licence agreements with Abbott and Centocor," Bridges said. "Peptech has never been better positioned."
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...